

Amendments to the Claims

Please cancel claims 2-4, 8, 9 and 14-18 without prejudice. Please amend the remaining claims as set forth in the List of Claims below.

List of Claims

1. (Currently amended) A method of determining whether a human female subject is at increased risk of having ovarian cancer relative to the general population, comprising:
 - (a) ~~removing~~ obtaining a test biological sample of urine from said subject;
 - (b) determining the amount of eosinophil-derived neurotoxin (EDN) in said test biological sample wherein said EDN is characterized by the amino acid sequence of SEQ ID NO:1;
 - (c) comparing the amount of EDN determined in step (b) with the amount in one or more control biological samples of urine; and
 - (d) concluding that said subject has or is likely to develop ovarian cancer if the amount of EDN in said test biological sample is significantly at least 20% higher than in said control biological samples.
- 2-4. Cancelled.
5. (Currently amended) The method of ~~any one of claims 1-4~~ claim 1, wherein the determination of EDN amount is accomplished using an immunoassay.
6. (Withdrawn-currently amended) The method of ~~any one of claims 1-4~~ claim 1, wherein the amount of EDN is determined by mass spectrometry.
7. (Withdrawn-currently amended) The method of ~~any one of claims 1-4~~ claim 1, wherein the amount of EDN is determined by surface enhanced laser desorption/ionization mass spectrometry.
- 8-9. Cancelled.

10. (Withdrawn-currently amended) The method of any one of ~~claims 1-4~~ claims 1 or 5-7, further comprising performing at least one additional assay for a diagnostic marker of cancer or other disease.
11. (Withdrawn) The method of claim 10, wherein said diagnostic marker is selected from the group consisting of: prostate specific antigen; BRCA-1 and BRCA-2.
12. (Withdrawn) The method of claim 10, wherein said diagnostic marker is CA 125.
13. (Currently amended) The method of any one of ~~claims 1-4~~ claims 1 or 5-7, wherein said subject is selected for testing based upon a clinical determination that she is at an elevated risk of having or developing ovarian cancer.
- 14-18. Cancelled